Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$60.08 +9.6%	$41.72	$30.04 ▼ $63.68	$4.73B	1.82	1.92 million shs	5.33 million shs
NBIX Neurocrine Biosciences	$133.51 +3.7%	$122.63	$84.23 ▼ $157.98	$12.74B	0.24	1.14 million shs	1.26 million shs
QGEN Qiagen	$48.03 +0.4%	$45.14	$37.63 ▼ $49.30	$10.64B	0.68	1.20 million shs	1.75 million shs
RGEN Repligen	$129.82 +1.0%	$125.94	$102.97 ▼ $182.52	$7.22B	1.11	723,549 shs	576,961 shs
TECH Bio-Techne	$52.59 -0.2%	$50.05	$46.01 ▼ $83.62	$8.26B	1.39	1.46 million shs	1.51 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	+9.60%	+16.28%	+42.74%	+75.36%	+9.18%
NBIX Neurocrine Biosciences	+3.71%	+3.18%	+6.19%	+47.17%	-6.83%
QGEN Qiagen	+0.40%	-1.15%	+4.03%	+19.81%	+23.32%
RGEN Repligen	+0.98%	+2.25%	-1.41%	+12.70%	+7.45%
TECH Bio-Techne	-0.17%	-1.11%	+5.43%	+6.76%	-26.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRSP CRISPR Therapeutics	2.4394 of 5 stars	3.3	1.0	0.0	0.0	3.0	2.5	0.6
NBIX Neurocrine Biosciences	4.766 of 5 stars	3.4	5.0	0.0	2.9	2.9	2.5	1.9
QGEN Qiagen	3.8835 of 5 stars	1.2	5.0	1.7	4.5	1.9	1.7	1.3
RGEN Repligen	4.7455 of 5 stars	4.3	2.0	0.0	4.5	2.1	1.7	1.9
TECH Bio-Techne	4.9548 of 5 stars	4.3	5.0	1.7	4.2	2.2	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.53	Moderate Buy	$71.75	19.42% Upside
NBIX Neurocrine Biosciences	2.86	Moderate Buy	$163.05	22.12% Upside
QGEN Qiagen	2.30	Hold	$49.40	2.85% Upside
RGEN Repligen	2.69	Moderate Buy	$170.75	31.53% Upside
TECH Bio-Techne	2.50	Moderate Buy	$71.36	35.70% Upside

Current Analyst Ratings Breakdown

Latest CRSP, QGEN, TECH, NBIX, and RGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	NBIX Neurocrine Biosciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$152.00 ➝ $174.00
7/9/2025	TECH Bio-Techne	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$65.00
7/8/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
7/8/2025	RGEN Repligen	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$140.00 ➝ $130.00
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00
6/27/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00
6/27/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00
6/26/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/26/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
6/26/2025	QGEN Qiagen	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $53.00
6/24/2025	QGEN Qiagen	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$55.00

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$37.31M	139.06	N/A	N/A	$22.64 per share	2.65
NBIX Neurocrine Biosciences	$2.36B	5.61	$3.51 per share	38.09	$25.58 per share	5.22
QGEN Qiagen	$2.00B	5.33	$3.22 per share	14.93	$16.05 per share	2.99
RGEN Repligen	$634.44M	11.50	$3.14 per share	41.38	$35.21 per share	3.69
TECH Bio-Techne	$1.16B	7.11	$2.31 per share	22.77	$13.13 per share	4.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)
NBIX Neurocrine Biosciences	$341.30M	$2.95	45.26	20.64	1.32	12.68%	11.81%	8.59%	7/30/2025 (Estimated)
QGEN Qiagen	$83.59M	$0.40	120.42	19.52	2.44	4.68%	14.61%	8.80%	8/5/2025 (Estimated)
RGEN Repligen	-$25.51M	-$0.45	N/A	55.01	3.68	-3.93%	4.53%	3.17%	7/29/2025 (Estimated)
TECH Bio-Techne	$168.10M	$0.82	64.13	26.70	2.50	10.89%	13.17%	10.17%	8/6/2025 (Estimated)

Latest CRSP, QGEN, TECH, NBIX, and RGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	NBIX Neurocrine Biosciences	$0.97	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q4 2025	TECH Bio-Techne	$0.49	N/A	N/A	N/A	$315.14 million	N/A
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.54	N/A	N/A	N/A	$6.44 million	N/A
7/30/2025	Q2 2025	QGEN Qiagen	$0.60	N/A	N/A	N/A	$523.97 million	N/A
7/29/2025	Q2 2025	RGEN Repligen	$0.40	N/A	N/A	N/A	$174.62 million	N/A
5/7/2025	Q1 2025	QGEN Qiagen	$0.50	$0.55	+$0.05	$0.41	$465.66 million	$483.46 million
5/7/2025	Q3 2025	TECH Bio-Techne	$0.51	$0.56	+$0.05	$0.14	$317.92 million	$316.18 million
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A
5/5/2025	Q1 2025	NBIX Neurocrine Biosciences	$0.70	$0.08	-$0.62	$0.08	$587.06 million	$572.60 million
4/29/2025	Q1 2025	RGEN Repligen	$0.35	$0.39	+$0.04	$0.10	$163.65 million	$169.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A
QGEN Qiagen	$0.25	0.52%	N/A	62.50%	N/A
RGEN Repligen	N/A	N/A	N/A	N/A	N/A
TECH Bio-Techne	$0.32	0.61%	N/A	39.02%	N/A

Latest CRSP, QGEN, TECH, NBIX, and RGEN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/1/2025	QGEN Qiagen		$0.25	0.52%	7/2/2025	7/3/2025	7/10/2025
5/19/2025	TECH Bio-Techne	quarterly	$0.08	0.67%	5/19/2025	5/19/2025	5/30/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	N/A	15.64	15.64
NBIX Neurocrine Biosciences	N/A	3.13	3.02
QGEN Qiagen	0.40	3.37	2.83
RGEN Repligen	0.27	6.79	5.79
TECH Bio-Techne	0.16	3.71	2.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
NBIX Neurocrine Biosciences	92.59%
QGEN Qiagen	70.00%
RGEN Repligen	97.64%
TECH Bio-Techne	98.95%

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	4.30%
NBIX Neurocrine Biosciences	4.80%
QGEN Qiagen	9.00%
RGEN Repligen	1.20%
TECH Bio-Techne	3.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	460	86.36 million	82.65 million	Optionable
NBIX Neurocrine Biosciences	1,800	98.97 million	94.22 million	Optionable
QGEN Qiagen	5,765	222.29 million	202.29 million	Optionable
RGEN Repligen	1,778	56.18 million	55.51 million	Optionable
TECH Bio-Techne	3,100	156.77 million	150.65 million	Optionable

CRSP, QGEN, TECH, NBIX, and RGEN Headlines

Recent News About These Companies

5 Revealing Analyst Questions From Bio-Techne’s Q1 Earnings Call

July 9 at 1:39 PM | msn.com

Bio-Techne (NASDAQ:TECH) Earns Buy Rating from Analysts at TD Cowen

July 9 at 8:40 AM | marketbeat.com

Bank of New York Mellon Corp Has $141.56 Million Position in Bio-Techne Corp (NASDAQ:TECH)

July 9 at 5:15 AM | marketbeat.com

Brown Advisory Inc. Has $112.12 Million Stock Position in Bio-Techne Corp (NASDAQ:TECH)

July 8 at 7:37 AM | marketbeat.com

New York State Teachers Retirement System Has $8.18 Million Stock Holdings in Bio-Techne Corp (NASDAQ:TECH)

July 5, 2025 | marketbeat.com

KBC Group NV Sells 5,601 Shares of Bio-Techne Corp (NASDAQ:TECH)

July 5, 2025 | marketbeat.com

1 S&P 500 Stock to Research Further and 2 to Keep Off Your Radar

July 3, 2025 | finance.yahoo.com

Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock - Nasdaq

July 2, 2025 | nasdaq.com

Allspring Global Investments Holdings LLC Sells 116,204 Shares of Bio-Techne Corp (NASDAQ:TECH)

July 1, 2025 | marketbeat.com

Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock

June 30, 2025 | zacks.com

Sumitomo Mitsui Trust Group Inc. Has $119.05 Million Stake in Bio-Techne Corp (NASDAQ:TECH)

June 30, 2025 | marketbeat.com

Bio-Techne Corp (NASDAQ:TECH) Shares Sold by Bessemer Group Inc.

June 30, 2025 | marketbeat.com

Asset Management One Co. Ltd. Has $8.01 Million Stock Holdings in Bio-Techne Corp (NASDAQ:TECH)

June 28, 2025 | marketbeat.com

Bio-Techne Corporation (TECH) Stock Price, Quote, News & Analysis - Seeking Alpha

June 27, 2025 | seekingalpha.com

13,589 Shares in Bio-Techne Corp (NASDAQ:TECH) Acquired by Lecap Asset Management Ltd.

June 26, 2025 | marketbeat.com

Bio-Techne, USP Partner to Enhance Monoclonal Antibody, Gene Therapy Development

June 25, 2025 | insidermonkey.com

Is Bio-Techne Stock Underperforming the Nasdaq?

June 25, 2025 | finance.yahoo.com

Bio-Techne Corporation: Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

June 24, 2025 | finanznachrichten.de

Bio-Techne and USP to accelerate monoclonal antibody and gene therapy product development

June 24, 2025 | msn.com

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

June 24, 2025 | prnewswire.com

Bio-Techne Corp (NASDAQ:TECH) Shares Sold by Envestnet Portfolio Solutions Inc.

June 24, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
Don’t Miss These 2 Small Quantum Stocks Poised to Pop
By Gabriel Osorio-Mazilli | June 24, 2025
View Don’t Miss These 2 Small Quantum Stocks Poised to Pop
3 Reasons AMD Could Be the Hottest Stock of the Summer
By Sam Quirke | June 20, 2025
View 3 Reasons AMD Could Be the Hottest Stock of the Summer
Oracle Stock Boils Higher, $300 Price Target in Sight
By Thomas Hughes | June 25, 2025
View Oracle Stock Boils Higher, $300 Price Target in Sight
Snag These 3 Bargain Tech Stocks Before They Pop
By Gabriel Osorio-Mazilli | June 27, 2025
View Snag These 3 Bargain Tech Stocks Before They Pop

CRSP, QGEN, TECH, NBIX, and RGEN Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$60.08 +5.26 (+9.60%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$62.64 +2.56 (+4.26%)

As of 07:02 AM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Neurocrine Biosciences NASDAQ:NBIX

$133.51 +4.77 (+3.71%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$134.25 +0.74 (+0.55%)

As of 07:00 AM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Qiagen NYSE:QGEN

$48.03 +0.18 (+0.38%)

Closing price 07/9/2025 03:57 PM Eastern

Extended Trading

$48.06 +0.03 (+0.06%)

As of 07:02 AM Eastern

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Repligen NASDAQ:RGEN

$129.82 +1.26 (+0.98%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$129.75 -0.07 (-0.05%)

As of 07:00 AM Eastern

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Bio-Techne NASDAQ:TECH

$52.59 -0.09 (-0.17%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$51.81 -0.78 (-1.48%)

As of 07:00 AM Eastern

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRSP, QGEN, TECH, NBIX, and RGEN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRSP, QGEN, TECH, NBIX, and RGEN Earnings

Compare Dividends

Latest CRSP, QGEN, TECH, NBIX, and RGEN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRSP, QGEN, TECH, NBIX, and RGEN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CRSP, QGEN, TECH, NBIX, and RGEN Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

Neurocrine Biosciences NASDAQ:NBIX

Qiagen NYSE:QGEN

Repligen NASDAQ:RGEN

Bio-Techne NASDAQ:TECH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools